 Amyotrophic Lateral Sclerosis
"Amyotrophic Lateral Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Descriptor ID |
D000690
|
| MeSH Number(s) |
C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050
|
| Concept/Terms |
Amyotrophic Lateral Sclerosis- Amyotrophic Lateral Sclerosis
- Lateral Scleroses, Amyotrophic
- Sclerosis, Amyotrophic Lateral
- Gehrig's Disease
- Gehrig Disease
- Gehrigs Disease
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Lou Gehrig's Disease
- Lou-Gehrigs Disease
- Disease, Lou-Gehrigs
- ALS (Amyotrophic Lateral Sclerosis)
- Lou Gehrig Disease
Amyotrophic Lateral Sclerosis, Guam Form- Amyotrophic Lateral Sclerosis, Guam Form
- Amyotrophic lateral sclerosis, Parkinsonism-Dementia Complex of Guam
- Amyotrophic lateral sclerosis, Parkinsonism Dementia Complex of Guam
- Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1
- Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1
- Guam Disease
- Disease, Guam
- Guam Form of Amyotrophic Lateral Sclerosis
|
Below are MeSH descriptors whose meaning is more general than "Amyotrophic Lateral Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Amyotrophic Lateral Sclerosis".
This graph shows the total number of publications written about "Amyotrophic Lateral Sclerosis" by people in UAMS Profiles by year, and whether "Amyotrophic Lateral Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2023 | 2 | 0 | 2 | | 2022 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2017 | 2 | 1 | 3 | | 2015 | 2 | 0 | 2 | | 2013 | 3 | 0 | 3 | | 2012 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Amyotrophic Lateral Sclerosis" by people in Profiles over the past ten years.
-
Roggenbuck J, Kaschalk M, Eustace R, Vicini L, Gokun Y, Harms MB, Kolb SJ. The Answer ALS return of results study: Answering the duty to disclose. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Nov; 25(7-8):743-750.
-
Ashrafzadeh-Kian S, Figdore D, Larson B, Deters R, Abou-Diwan C, Bornhorst J, Algeciras-Schimnich A. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays. Clin Chim Acta. 2024 Jul 15; 561:119817.
-
Gebrehiwet P, Brekke J, Rudnicki SA, Mellor J, Wright J, Earl L, Ball N, Iqbal H, Thomas O, Castellano G. Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May; 25(3-4):345-357.
-
Shefner JM, Jacobsen B, Kupfer S, Malik FI, Meng L, Wei J, Wolff AA, Rudnicki SA. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb; 25(1-2):162-169.
-
Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotroph Lateral Scler Frontotemporal Degener. 2023 08; 24(5-6):523-534.
-
Skajaa N, Riahi EB, Sz?pligeti SK, Horv?th-Puh? E, S?rensen TT, Henderson VW, S?rensen HT. Type 2 diabetes, obesity, and risk of amyotrophic lateral sclerosis: A population-based cohort study. Brain Behav. 2023 06; 13(6):e3007.
-
Ganne A, Balasubramaniam M, Ayyadevara H, Kiaei L, Shmookler Reis RJ, Varughese KI, Kiaei M. In silico analysis of TUBA4A mutations in Amyotrophic Lateral Sclerosis to define mechanisms of microtubule disintegration. Sci Rep. 2023 02 06; 13(1):2096.
-
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Butzner M, Chi? A, Andrews JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, Shefner JM. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. J Med Econ. 2023 Jan-Dec; 26(1):488-493.
-
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Chi? A, Andrews JA, Genge A, Jackson CE, Lechtzin N, Miller TM, Shefner JM. MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2023 05; 24(3-4):304-310.
-
Riechers SP, Mojsilovic-Petrovic J, Belton TB, Chakrabarty RP, Garjani M, Medvedeva V, Dalton C, Wong YC, Chandel NS, Dienel G, Kalb RG. Neurons undergo pathogenic metabolic reprogramming in models of familial ALS. Mol Metab. 2022 06; 60:101468.
-
Skajaa N, Bakos I, Horv?th-Puh? E, Henderson VW, Lash TL, S?rensen HT. Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study. Epidemiology. 2021 09 01; 32(5):756-762.
-
Sadr AS, Abdollahpour Z, Aliahmadi A, Eslahchi C, Nekouei M, Kiaei L, Kiaei M, Ghassempour A. Detection of structural and conformational changes in ALS-causing mutant profilin-1 with hydrogen/deuterium exchange mass spectrometry and bioinformatics techniques. Metab Brain Dis. 2022 01; 37(1):229-241.
-
Rudnicki SA, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Shefner JM. Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2022 05; 23(3-4):263-270.
-
Kiaei L, Kiaei M. RNA as a source of biomarkers for amyotrophic lateral sclerosis. Metab Brain Dis. 2022 08; 37(6):1697-1702.
-
Rudnicki SA, Andrews JA, Bian A, Cockroft BM, Cudkowicz ME, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM. Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 11; 22(7-8):486-494.
-
Sadr AS, Eslahchi C, Ghassempour A, Kiaei M. In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis. Sci Rep. 2021 03 25; 11(1):6849.
-
Rudnicki SA. Editorial to the supplement entitled "assessments of pulmonary function in patients with amyotrophic lateral sclerosis: options and applicability in both the clinical care and clinical trial settings". Amyotroph Lateral Scler Frontotemporal Degener. 2021; 22(sup1):2-4.
-
Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 05; 22(3-4):287-299.
-
Abdelaal AY, Mousa MH, Gamal M, Khalil MI, Elbasiouny SM, Eldawlatly S. A Classification Approach to Recognize the Firing of Spinal Motoneurons in Amyotrophic Lateral Sclerosis. Annu Int Conf IEEE Eng Med Biol Soc. 2020 07; 2020:3680-3683.
-
S?rensen TT, Horv?th-Puh? E, N?rgaard M, Ehrenstein V, Henderson VW. Risk of amyotrophic lateral sclerosis and other motor neuron disease among men with benign prostatic hyperplasia: a population-based cohort study. BMJ Open. 2019 07 04; 9(7):e030015.
-
Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0(0):1-11.
-
Barham C, Fil D, Byrum SD, Rahmatallah Y, Glazko G, Kiaei M. RNA-Seq Analysis of Spinal Cord Tissues from hPFN1G118V Transgenic Mouse Model of ALS at Pre-symptomatic and End-Stages of Disease. Sci Rep. 2018 09 13; 8(1):13737.
-
Nekouei M, Ghezellou P, Aliahmadi A, Arjmand S, Kiaei M, Ghassempour A. Changes in biophysical characteristics of PFN1 due to mutation causing amyotrophic lateral sclerosis. Metab Brain Dis. 2018 12; 33(6):1975-1984.
-
Kiaei M, Balasubramaniam M, Govind Kumar V, Shmookler Reis RJ, Moradi M, Varughese KI. ALS-causing mutations in profilin-1 alter its conformational dynamics: A computational approach to explain propensity for aggregation. Sci Rep. 2018 08 30; 8(1):13102.
-
Andersen JA. Amyotrophic Lateral Sclerosis and a "Death With Dignity". Omega (Westport). 2020 Sep; 81(4):567-576.
-
Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH. Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotroph Lateral Scler Frontotemporal Degener. 2018 08; 19(5-6):331-341.
-
Ling KK, Jackson M, Alkam D, Liu D, Allaire N, Sun C, Kiaei M, McCampbell A, Rigo F. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiol Dis. 2018 06; 114:174-183.
-
Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 01 01; 75(1):58-64.
-
Setter DO, Runge EM, Schartz ND, Kennedy FM, Brown BL, McMillan KP, Miller WM, Shah KM, Haulcomb MM, Sanders VM, Jones KJ. Impact of peripheral immune status on central molecular responses to facial nerve axotomy. Brain Behav Immun. 2018 02; 68:98-110.
-
Commean PK, Smith KE, Hildebolt CF, Bohnert KL, Sinacore DR, Prior FW. A Candidate Imaging Marker for Early Detection of Charcot Neuroarthropathy. J Clin Densitom. 2018 Oct - Dec; 21(4):485-492.
-
Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, Compadre CM, Goellner JJ, O'Brien CA, Fahmi T, Basnakian AG, Calingasan NY, Klessner JL, Beal FM, Peters OM, Metterville J, Brown RH, Ling KKY, Rigo F, Ozdinler PH, Kiaei M. Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet. 2017 02 15; 26(4):686-701.
-
Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M. Preferential PPAR-a activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet. 2016 Jan 15; 25(2):317-27.
-
Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015 Nov; 33(4):889-908.
-
DeLoach A, Cozart M, Kiaei A, Kiaei M. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opin Drug Discov. 2015 Oct; 10(10):1099-118.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|